<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: TPG GP A, LLC -->
          <cik>0001903793</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.01 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>11/06/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000318306</issuerCik>
        <issuerName>Abeona Therapeutics Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>00289Y206</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>6555 CARNEGIE AVE, 4TH FLOOR</com:street1>
          <com:city>Cleveland</com:city>
          <com:stateOrCountry>OH</com:stateOrCountry>
          <com:zipCode>44103</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>TPG GP A, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4761050.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4761050.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4761050.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.0</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock ("Common Stock") outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by Abeona Therapeutics Inc. (the "Issuer") with the Securities and Exchange Commission (the "Commission") on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>COULTER, JAMES G</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4761050.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4761050.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4761050.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.0</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>WINKELRIED JON</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>4761050.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>4761050.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4761050.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.0</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The percentage beneficial ownership set forth in response to Item 11 above assumes that there is a total of 68,041,223 shares of Common Stock outstanding, which is the sum of the (i) 57,146,840 shares of Common Stock outstanding as of November 5, 2026, as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Commission on November 9, 2026, (ii) 4,494,383 shares of Common Stock issued in connection with the Asset Purchase Agreement the Issuer entered into on November 6, 2026, and (iii) 6,400,000 shares of Common Stock issued in a private placement on November 10, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Abeona Therapeutics Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>6555 Carnegie Avenue, 4th Floor, Cleveland OH 44103</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13G is being filed jointly by TPG GP A, LLC, a Delaware limited liability company ("TPG GP A"), James G. Coulter and Jon Winkelried (each, a "Reporting Person" and, together, the "Reporting Persons"), pursuant to an Agreement of Joint Filing incorporated by reference herein in accordance with Rule 13d-1(k)(1) under the Act.

TPG GP A exercises direct or indirect control over entities that collectively hold 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc., a Delaware corporation, which is the sole member of TPG GPCo, LLC, a Delaware limited liability company, which is the sole member of TPG Holdings II-A, LLC, a Delaware limited liability company, which is the general partner of TPG Operating Group II, L.P., a Delaware limited partnership, which is the sole member of each of (i) TPG Holdings I-A, LLC, a Delaware limited liability company, and (ii) TPG Holdings III-A, LLC, a Cayman Islands limited liability company. TPG Holdings I-A, LLC is the general partner of TPG Operating Group I, L.P., a Delaware limited partnership, which is the sole member of TPG LSI GenPar Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG LSI GenPar, L.P., a Delaware limited partnership, which is the sole member of TPG LSI SPV GP, LLC, a Delaware limited liability company, which is the general partner of TPG LSI Rise Ellodi, L.P., a Delaware limited partnership ("TPG Ellodi"), which directly holds 266,667 shares of Common Stock. TPG Holdings III-A, LLC is the general partner of TPG Holdings III-A, L.P., a Cayman Islands limited partnership, which is the general partner of TPG Operating Group III, L.P., a Delaware limited partnership, which is the sole shareholder of TPG GenPar VI-AIV Advisors, Inc., a Cayman Islands exempted company, which is the general partner of TPG GenPar VI-AIV, L.P., a Cayman Islands limited partnership, which is the general partner of TPG Valley Aggregation, L.P., a Cayman Islands limited partnership, which is the controlling member of Valley Holdings GP, LLC, a Cayman Islands limited liability company, which is the general partner of TPG Valley, L.P., a Cayman Islands limited partnership, which is the sole shareholder of Ellodi Pharmaceuticals Holdings GenPar, Ltd., a Cayman Islands limited company, which is the general partner of Ellodi Pharmaceuticals Holdings, L.P., a Cayman Islands limited partnership, which is the sole member of Ellodi Development I GenPar, LLC, a Delaware limited liability company, which is the general partner of Ellodi Pharmaceuticals, L.P., a Delaware limited partnership (together with TPG Ellodi, the "Holders"), which directly holds 4,494,383 shares of Common Stock.

Because of the relationship of TPG GP A to the Holders, TPG GP A may be deemed to be the beneficial owner of the shares of Common Stock held by the Holders. TPG GP A is controlled by entities owned by Messrs. Coulter and Winkelried. Because of the relationship of Messrs. Coulter and Winkelried to TPG GP A, each of Messrs. Coulter and Winkelried may be deemed to be the beneficial owners of the shares of Common Stock held by the Holders. Messrs. Coulter and Winkelried disclaim beneficial ownership of such shares of Common Stock held by the Holders except to the extent of their pecuniary interest therein.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The principal business address of each of the Reporting Persons is as follows:

c/o TPG Inc.
301 Commerce Street, Suite 3300
Fort Worth, Texas 76102</principalBusinessOfficeOrResidenceAddress>
        <citizenship>See response to Item 4 of each of the cover pages.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See responses to Item 9 on each cover page.</amountBeneficiallyOwned>
        <classPercent>See responses to Item 11 on each cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See responses to Item 5 on each cover page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See responses to Item 6 on each cover page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See responses to Item 7 on each cover page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See responses to Item 8 on each cover page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>See response to Item 2(a) above.</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.*
* Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Commission as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>TPG GP A, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Matthew White</signature>
        <title>Matthew White / Vice President</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>COULTER, JAMES G</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Gerald Neugebauer</signature>
        <title>Gerald Neugebauer on behalf of James G. Coulter (1)</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>WINKELRIED JON</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Gerald Neugebauer</signature>
        <title>Gerald Neugebauer on behalf of Jon Winkelried (2)</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>(1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617).

(2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).</signatureComments>
  </formData>
</edgarSubmission>
